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Abstract
Background: The objective was to evaluate the cost-
effectiveness of NEPA, an oral fixed combination netupitant 
(NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with 
aprepitant and palonosetron (APPA) or palonosetron (PA) alone, 
to prevent chemotherapy-induced nausea and vomiting (CINV) 
in patients undergoing treatment with highly or moderately 
emetogenic chemotherapy (HEC or MEC) in the UK.
Scope: A systematic literature review and meta-analysis were 
undertaken to compare NEPA with currently recommended 
anti-emetics. Relative effectiveness was estimated over the 
acute (day 1) and overall treatment (days 1–5) phases, taking 
complete response (CR, no emesis and no rescue medication) 
and complete protection (CP, CR and no more than mild 
nausea [VAS scale <25 mm]) as primary efficacy outcomes. A 
three-health-state Markov cohort model, including CP, CR and 
incomplete response (no CR) for HEC and MEC, was constructed. 
A five-day time horizon and UK NHS perspective were adopted. 
Transition probabilities were obtained by combining the 
response rates of CR and CP from NEPA trials and odds ratios 
from the meta-analysis. Utilities of 0.90, 0.70 and 0.24 were 
defined for CP, CR and incomplete response, respectively. Costs 
included medications and management of CINV-related events 
and were obtained from the British National Formulary and NHS 
Reference Costs. The expected budgetary impact of NEPA was 
also evaluated.
Findings: In HEC patients, the NEPA strategy was more effective 
than APPA (quality-adjusted life days [QALDs] of 4.263 versus 
4.053; incremental emesis-free and CINV-free days of +0.354 
and +0.237, respectively) and was less costly (£80 versus £124), 
resulting in NEPA being the dominant strategy. In MEC patients, 
NEPA was cost effective, cumulating in an estimated 0.182 extra 
QALDs at an incremental cost of £6.65 compared with PA.
Conclusion: Despite study limitations (study setting, time 
horizon, utility measure), the results suggest NEPA is cost 
effective for preventing CINV associated with HEC and MEC in 
the UK.
Keywords: antiemetics, cost-effectiveness, medical oncology, 
meta-analysis, nausea, netupitant, palonosetron, quality of life, 
review literature, vomiting.
Abbreviations: 5-HT3, 5-HT3 receptor antagonist; AE, 
adverse event; APPA, aprepitant and palonosetron; APR, 
aprepitant; ASCO, American Society of Clinical Oncology; 
BNF, British National Formulary; CI, confidence interval; 
CINV, chemotherapy-induced nausea and vomiting; CP, 
complete protection; CR, complete response; CrI, credible 
interval; DIC, deviance information criterion; DSA, deterministic 
sensitivity analysis; ESMO, European Society for Medical 
Oncology; HEC, highly emetogenic chemotherapy; HTA, 
health technology assessment; ICER, incremental cost-
effectiveness ratio; IV, intravenous; MASCC, The Multinational 
Association of Supportive Care in Cancer; MEC, moderately 
emetogenic chemotherapy; mg, milligram; MIMS, Monthly 
Index of Medical Specialities; MTC, Mixed Treatment 
Comparison; NA, not available; NCCN, National Comprehensive 
Cancer Network; NEPA, netupitant and palonosetron fixed 
combination; NETU, netupitant; NHS, National Health Service; 
NICE, National Institute for Health and Clinical Excellence; NK1, 
NK1 receptor antagonist; OR, odds ratio; PA, palonosetron; 
PICOS, Population, Interventions, Comparators, Outcomes 
and Study design; PO, per os; PSA, probabilistic sensitivity 
analysis; PSSRU, Personal Social Services Research Unit; QALD, 
quality-adjusted life-days; QALY, quality-adjusted life-years; RA, 
receptor antagonist; RR, response rate; TC, total control; UK, 
United Kingdom; VAS, visual analogue scale; WTP, willingness  
to pay
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Introduction
Chemotherapy-induced nausea and vomiting (CINV) is among 
the most common and feared side effects reported by cancer 
patients and may appear prior to, during or after chemotherapy 
administration [1]. The development of CINV is a complex 
process involving the activation of several neurotransmitters, 
which interact with the central nervous system stimulating 
a physiological response [2,3]. The incidence of CINV ranges 
from less than 10% in patients treated with chemotherapy 
agents with minimal emetic risk, from 30% to 90% in patients 
with agents with medium risk, to >90% among those whose 
regimens contain an agent with a high emetic risk [1].
Nausea and emesis, particularly when occurring during the 
delayed phase (days 2–5 of the chemotherapy cycle), cause 
significant problems for patients with cancer. CINV can lead 
to severe clinical conditions such as electrolyte imbalance 
and dehydration, and can affect a patient’s quality of life and 
willingness to continue chemotherapy [4]. CINV also exerts a 
considerable financial burden on the healthcare system. Direct 
medical costs associated with managing CINV are driven by 
the cost of rescue medications, unscheduled physician visits, 
emergency room visits and hospitalisations [5–10].
Several anti-emetic therapies are used to prevent CINV. 
The Multinational Association of Supportive Care in Cancer 
(MASCC)/European Society for Medical Oncology (ESMO), 
American Society of Clinical Oncology (ASCO) and National 
Comprehensive Cancer Network (NCCN) guidelines are used 
to direct clinical practice and treatment in the UK. It has been 
suggested that with the correct use of anti-emetics, CINV could 
be prevented in 70%–80% of patients; however, suboptimal 
CINV control remains an issue in clinical practice. Many patients 
receiving highly or moderately emetogenic chemotherapy 
(HEC or MEC) still experience acute and delayed nausea, 
vomiting or both. In particular, current treatments provide 
insufficient CINV control during the delayed phase [11,12].
While guidelines for preventing CINV are widely available, 
clinical uptake of guidelines remains low [13,14]. The reasons 
for non-adherence to clinical guidelines are multifactorial. A 
key aspect involves individual clinicians disagreeing with the 
key recommendations of the guidelines [15,16]. Non-adherence 
may also reflect economic constraints of hospitals and 
government payers considering the higher costs of branded 
anti-emetic therapies [13]. 
NEPA is indicated in Europe for the prevention of the acute and 
delayed nausea and vomiting associated with HEC and MEC. 
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Two trials have been conducted examining NEPA, including 
one phase II dose ranging study, one phase III efficacy and one 
phase III safety trial.
The primary objective of this study was to assess, from the 
United Kingdom (UK) payer perspective, the cost-effectiveness 
of NEPA compared to the extemporaneous combination 
aprepitant plus palonosetron for patients receiving HEC and to 
palonosetron alone for patients receiving MEC.
Methods
Systematic review
A systematic literature review was undertaken to identify all 
relevant clinical trials examining the efficacy of NEPA and its 
comparators in the prevention of CINV for patients undergoing 
HEC or MEC as treatment for cancer. The systematic literature 
review focused on English-language publications with the 
methodological approach in line with established systematic 
review procedures.
The scope of the literature review was defined in terms of 
Population, Interventions, Comparators, Outcomes and Study 
design (PICOS) [17]. Eligible studies included human adult 
(≥18 years) cancer patients receiving highly or moderately 
emetogenic chemotherapy that assessed the efficacy or 
safety of one of the anti-emetics (e.g. 5 HT-3s, NK1s, other) by 
comparing the intervention with either placebo or an active 
comparator. Studies were required to contain at least complete 
response and other outcomes like complete protection, partial 
response, complete control, total control, time to first emetic 
episode, time to use of rescue medication or time to treatment 
failure, and to be blinded, randomised controlled trials  
(≥ Phase II) with more than 50 patients (Appendix 1). Studies 
were excluded if they were duplicate, animal or in vitro  
studies, narrative reviews, editorials, case reports or letters, 
meta-analyses, were not in English language or if they had the 
wrong scope, population, intervention, or did not contain the 
correct study type or outcome of interest. Any disagreements 
between authors were resolved by a third party.
The electronic search was performed in MEDLINE, EMBASE, 
the Cochrane Collaboration, and HTA in Cochrane. The search 
was conducted with limits of ‘English language’ with the 
date limit from 2000 to 28/08/2013 for all searches except 
olanzapine, which was included in an updated search which 
ranged up to 09/01/2014. Although olanzapine was not 
recommended in ASCO or MASCC as a preferred preventative 
Cawston H, Bourhis F, Eriksson J, Ruffo P, D’Agostino P, Turini M, et al. Drugs in Context 2017; 6: 212298. DOI: 10.7573/dic.212298 3 of 13
ISSN: 1740-4398
REVIEW – Cost-effectiveness of netupitant and palonosetron in CINV drugsincontext.com
treatment for CINV, it was later included in the search 
because of its inclusion in the NCCN guidelines at the time 
of the updated search. A data table was produced, with key 
information extracted from the eligible papers including study 
authors, date, title, study design, treatment strategies, patient 
characteristics, chemotherapy received, results/outcomes 
and adverse events. In addition, the quality assessment and 
evaluation of each study was undertaken using the National 
Institute for Health and Clinical Excellence (NICE) checklist for 
randomised controlled trials [18].
Meta-analysis
Following the systematic literature review and a feasibility 
assessment, which included an evaluation of available evidence 
and a heterogeneity assessment, it was considered feasible 
to undertake an indirect comparison within a frequentist 
framework in the MEC indication and a Bayesian Mixed 
Treatment Comparison (MTC) in the HEC and AC-MEC indication.
Three efficacy outcomes were analysed: complete response 
(CR), complete protection (CP) and total control (TC). CR is the 
efficacy outcome most commonly reported in CINV treatment 
studies, defined as no nausea, no vomiting, and no use of 
rescue medication (with studies not defining CR in this way 
excluded). The definition of CP was no emetic episodes, no use 
of rescue medication, and no more than mild nausea (defined 
as Visual Analogue Scale, VAS <25 mm). A subgroup of patients 
who achieve CR also achieve TC, defined as no emesis, no use 
of rescue medication, and no nausea (<5 mm on the VAS). 
For each outcome, where data were available, results were 
presented for two different time periods: the acute phase (day 
1) and the overall phase (days 1–5). 
In the MEC population, an indirect treatment comparison 
of CR was performed using fixed effect models, as the 
inclusion of random effects was considered not appropriate 
given the low number of studies available and that CR was 
the only outcome sufficiently reported. MTC models were 
performed in the HEC population using both fixed and random 
effects where the model best fitting the data was selected 
based on the deviance information criterion (DIC) [19,20]. 
The MTC allowed the comparative effect size of treatments 
on a specific outcome scale to be estimated, as well as the 
treatment-specific probability of being the best for some 
characteristics. The odds ratio was presented as the primary 
efficacy outcome measure for each analysis. The uncertainty 
associated with the measure has been reported via the 95% 
confidence interval (CI) for the indirect comparison in the MEC 
population, and the credible intervals (CrI) for the MTC analyses 
in the HEC population.
Economic evaluation
Cost-utility Markov models were developed to estimate 
the expected cost and health outcomes after HEC or MEC 
administration, to compare NEPA against aprepitant combined 
with palonosetron (APPA) in the HEC population and against 
palonosetron in the MEC population (Figure 1). 
The target patient population was cancer patients receiving 
prophylactic anti-emetics for the management of HEC or MEC. 
The selection of relevant comparators to NEPA was based on 
international clinical guidelines [21–23]. The perspective was 
that of the UK National Health Service (NHS). The time horizon 
for the model was five days that consist of the first day (acute 
phase) and from the first to fifth day (overall phase) and was run 
for one cycle of chemotherapy [11].
All patients entered the Markov model on the first day after 
the chemotherapy administration, for HEC and MEC regimens, 
respectively. In the acute phase (day 1), patients had different 
probabilities of achieving complete response and incomplete 
response, depending on the efficacy of the administered anti-
emetic, obtained from the meta-analysis. Complete response 
was divided into two subcategories: complete protection and 
complete response at best (complete response without complete 
protection). The same approach was taken to assess the patient 
distribution in each state at the end of day 5 (i.e. response rate in 
overall phase). To determine the number of patients in each state 
between the second and the fourth day, the patient flow on days 
2–4 was calibrated using linear interpolation between both the 
acute and overall phase-response rates.
The response rates were obtained from NEPA trials (Table 1). 
The efficacies of the comparators were obtained by combining 
the response rates of NEPA and the ORs calculated in the meta-
analysis as detailed in the equation below:
Response rate
Response Rate
OR (1 Response Rate ) Response RateT
NEPA
NEPAvsT NEPA NEPA
=
× − +
where T is a treatment comparator of NEPA and ORNEPAvsT  is the 
odds ratio of NEPA versus this treatment, as obtained from the 
meta-analysis.
The odds ratios of each considered treatment regimen 
compared to NEPA are presented in Table 2 for the HEC and 
MEC populations.
Figure 1. A structure of the Markov cohort model. 
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Table 1. Response rates of NEPA (95% CI).
HEC MEC
NEPA 07-07  
(n=135)
NEPA 08-18  
(n=724)
RR (95% CI) RR (95% CI)
Acute 
phase
Complete 
response
0.985a (0.965–0.999) 0.884a (0.859–0.905)
Complete 
protection
0.970a (0.942–0.999) 0.823 (0.794–0.849)
Overall 
phase
Complete 
response
0.896a (0.845–0.948) 0.743b (0.71–0.774)
Complete 
protection
0.830a (0.766–0.893) 0.638a (0.602–0.672)
CI: confidence interval; HEC: highly emetogenic 
chemotherapy; MEC: moderately emetogenic 
chemotherapy; NA: not available; NEPA: netupitant+ 
palonosetron+dexamethasone; RR: response rate.
ap≤0.05, bp≤0.0001.
Table 2. Estimated odds ratios of the comparators 
in HEC and MEC. 
HEC
APPAa
MEC
PAb
OR (95% CI) OR (95% CI)
Acute 
phase
Complete 
response
1.498 (0.217–6.385) 1.345 (0.879–2.063)
Complete 
protection
3.501 (1.088–13.263) 1.084 (0.745–1.577)
Overall 
phase
Complete 
response
2.490 (1.103–6.092) 1.450 (1.050–2.003)
Complete 
protection
3.501 (1.088–13.263) 1.281 (0.947–1.724)
aaprepitant+palonosetron+dexamethasone; 
bpalonosetron+dexamethasone.
CI: confidence interval; HEC: highly emetogenic  
chemotherapy; MEC: moderately emetogenic  
chemotherapy; NEPA: netupitant+palonosetron+ 
dexamethasone; OR: odds ratio.
Reference efficacy was NEPA from NETU 07-07 and NETU 
08-18 for HEC and MEC, respectively.
Table 3. Cost of treatment and healthcare resource 
use (£, 2013). 
Treatments PO IV
NEPAa 71.17 NA
APPAb 105.48 106.04
APR+ONDc 57.09 67.24
APR+GRAd 59.66 51.75
OLA+PAe 57.59 NA
PAf 56.61 58.62
ONDg 8.23 19.82
GRAh 10.79 4.33
Healthcare resource Cost per patient
Hospitalisation 68.27
Rescue medication 2.05
Outpatient/physician visit 13.57
anetupitant+palonosetron+dexamethasone; 
baprepitant+palonosetron+dexamethasone; 
caprepitant+ondansetron+dexamethasone; 
daprepitant+granisetron+dexamethasone; 
eolanzapine+palonosetron+dexamethasone; 
fpalonosetron+dexamethasone; 
gondansetron+dexamethasone; 
hgranisetron+dexamethasone; IV: intravenous; NA: not 
applicable; PO: per os (by mouth).
In previously published economic models for CINV, an anchor 
utility of 0.90 was used for chemotherapy without nausea and 
vomiting and a utility of 0.20 was used for the ‘incomplete 
response’ health state, in which emesis and/or nausea are 
present [24,25]. A value of 0.24 for the incomplete response 
state was adjusted based on clinical expert feedback. Given that 
‘chemotherapy without nausea and vomiting’ anchor value is 0.90, 
the utility for the mild nausea state from Borjeson et al. (0.752) was 
assumed to be 0.70 for the complete response at best [26]. The 
utility value for total control was assumed to be 0.95 in order to 
linearise between perfect health (1.00) and complete protection 
(0.90). Finally, utilities of 0.90, 0.70 and 0.24 were defined for CP, CR 
and incomplete response, respectively [24,25,27]. 
Treatment costs of the prophylactic anti-emetic comparators 
were calculated based on recommended doses from 
international guidelines and local unit costs in the UK as 
found in the British National Formulary (BNF) 2014, the Personal 
Social Services Research Unit (PSSRU) 2013 and the NHS reference 
costs 2012–13 [21–23]. The costs of NEPA were calculated upon 
the price assumption £69 per package of 300 mg, as published 
by UK Monthly Index of Medical Specialities (MIMS). The cost per 
patient per cycle of health resources used due to emetic events 
were based on a study among cancer patients receiving a broad 
range of MEC in a trial setting in the UK [28]. The different costs 
used in the model are detailed in Table 3.
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The primary outcome measure used in the analysis was 
the incremental cost-effectiveness ratio (ICER) defined as 
the ratio of the incremental difference in total cost to the 
incremental difference in benefits between two treatment 
strategies. It can be expressed as the cost per life-year gained 
or by quality-adjusted life years (QALYs) by multiplying the 
years of life with a weight, measured in utilities, reflecting 
quality of life. 
Sensitivity analyses were conducted in order to assess 
the impact of parameter and structural uncertainty on 
results. The Deterministic Sensitivity Analysis (DSA) showed 
the extent to which the results are affected by sources or 
assumptions and continuous variables (e.g. efficacy, costs, 
and utilities) increasing and reducing by 25% of the values. 
In addition to the DSAs, a probabilistic sensitivity analysis 
(PSA) was conducted in the model. A PSA allows capturing 
interactions between several inputs by running the model a 
large number of times (typically at least 1000 times) as a  
Monte Carlo simulation, using randomly drawn sets of  
inputs. The possible inputs are defined by assigning a  
statistical distribution around the mean value of each  
uncertain parameter, reflecting the extent and nature of 
dispersion around the mean. For each run, values are  
sampled at random from each distribution, and the decision 
tree is rolled back using these values to obtain a (cost-
effectiveness) pair.
Results
Systematic review and meta-analysis
The search of randomised trials examining anti-emetics in 
adult cancer patients returned a total of 2060 results across 
the four screened databases. After the removal of duplicates, 
1749 abstracts were reviewed and of these 208 full-text articles 
were evaluated. Titles, abstracts and full texts were screened 
by two independent reviewers. Discrepancies were resolved 
by a third reviewer. A total of 37 studies were deemed eligible 
for inclusion. Details on counts and reasons for exclusion are 
reported in Figure 2.
Figure 2. Literature review flow chart.
Central
N=291
Duplicates
N=311
Medline
N=399
Embase
N=1367
Titles/Abstracts
N=2060
Full-texts to review
N=208
37 studies included
Excluded (N=171)
Duplicate (N=20)
Wrong scope (N=3)
Wrong population (N=10)
Wrong intervention (N=5)
No outcome of interest (N=17)
Complete response not dened or
wrong denition (N=25)
Wrong study type (N=45)
Less than 50 patients (N=15)
Unobtainable/insucient
information to include (N=17)
Not published in English (N=14)
HTA
N=3
Excluded (N=1541)
- Duplicate (N=9)
- Wrong scope (N=790)
- Wrong population (N= 52)
- Wrong intervention (N=144)
- No outcome of interest (N=1)
- Wrong study type (N=536)
- Less than 50 patients (N=3)
- Unobtainable/insucient 
information to include (N= 6)
Titles/Abstracts to review
N=1749
HTA: health technology assessment.
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life-days (QALDs) gain of NEPA compared to APPA was 0.21 days 
(=0.0006 years). Thus NEPA was a cost-saving treatment against 
APPA. Given the threshold for willingness to pay (WTP) of 
£30,000, the net benefit (NB) of NEPA against palonosetron was 
£62 with an acceptability of 97%.
In MEC patients, although the cost per CINV episode was less 
costly in the NEPA arm, the incremental drug cost resulted in 
NEPA being more costly overall. Compared to palonosetron 
(PA), the incremental cost of NEPA was £6.65 while the 
QALD gain was 0.18 days (=0.0005 QALYs), which gives an 
ICER of approximately £13,318. Given a threshold of WTP of 
£30,000, the NB of NEPA against palonosetron was £8 with an 
acceptability of 88%.
The results of the meta-analysis were directly used as 
efficacy inputs for the comparators. They are summarised in 
Appendixes 2 and 3 for HEC and MEC respectively.
Cost-effectiveness
In the base case analysis, NEPA was evaluated against the 
relevant comparators. The results of the analyses are presented 
in Table 4 for HEC and MEC. 
In HEC patients, given the price assumption for NEPA, the 
treatment-acquisition costs and the cost per CINV episode 
management were lower in the NEPA arm. The quality-adjusted 
Table 4. Base case analysis of NEPA compared to other treatments in HEC and MEC.
HEC MEC
APPA(PO) NEPA(PO) PA(PO) NEPA(PO)
COSTS (£)
Treatment acquisition 105.48 71.17 56.61 69.72
CINV episode management 18.81 8.72 28.02 21.56
 Inpatient care 15.31 7.10 22.80 17.55
 Rescue medication 0.46 0.21 0.68 0.53
 Outpatient/physician care 3.04 1.41 4.53 3.49
Cost in acute phase 1.87 1.26 12.59 9.73
Cost in delayed phase 16.94 7.47 15.44 11.83
Cost of treated related AEs 0.00 0.00 0.00 0.00
Indirect costs, other expenses 0.00 0.00 0.00 0.00
Indirect costs, workday loss 0.00 0.00 0.00 0.00
Total costs 124.29 79.89 84.63 91.28
HEALTH OUTCOMES
Average emesis-free days 4.348 4.703 3.769 4.068
Average CINV-free days 4.273 4.500 3.428 3.653
Emesis-free patients (%) 77.6 89.6 66.6 74.3
CINV-free patients (%) 77.6 83.0 57.9 63.8
Quality-adjusted life days 4.055 4.263 3.619 3.802
Quality-adjusted life years 0.011 0.012 0.010 0.010
COST/OUTCOMES (£)
Cost per emesis-free day   Dominant   86
Cost per CINV-free day Dominant 113
Cost per QALDs gain   Dominant   36
Cost per QALYs gain   Dominant   13,318
WILLINGNESS-TO-PAY (£30,000)
Net monetary benefit £62 £8
Acceptability 97% 88%
AE: adverse event; APPA: aprepitant+palonosetron+dexamethasone; CINV: chemotherapy induced nausea and vomiting;  
HEC: highly emetogenic chemotherapy; MEC: moderately emetogenic chemotherapy; NEPA: netupitant+palonosetron+ 
dexamethasone; PA: palonosetron+dexamethasone; PO: per os (by mouth); QALD: quality-adjusted life-days; QALY:  
quality-adjusted life-years. 
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In the one-way sensitivity analysis, the effect of positively 
and negatively varying the continuous input variables by 
25% and selecting alternative sources and assumptions were 
explored. The results of the sensitivity analyses are presented 
in a tornado diagram in Figure 3. The considered parameter 
variations resulted in NEPA always being the dominant strategy 
with negative incremental costs and positive incremental 
QALYs.
A probabilistic sensitivity analysis (PSA) sampling 1000 
simulations was conducted. The results of the PSA are presented 
as scatterplots of incremental effects and costs (Figure 4) for the 
HEC and MEC populations. In HEC patients, NEPA was a dominant 
strategy in 89.2% of simulations against APPA and was cost saving 
but less effective in 10.4% of cases. Similarly, NEPA was a dominant 
strategy in 80.4% of simulations against palonosetron and cost 
saving but less effective in 0.1% of cases in the MEC population. 
Figure 3. Tornado diagram of one-way sensitivity analysis in HEC and MEC.
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Discussion
The primary objective of the analysis was to evaluate the 
cost-effectiveness of NEPA for the treatment of CINV in terms 
of the UK payer perspective. The evaluation was implemented 
by emetogenic level of chemotherapy, that is, HEC and MEC 
indications. The most relevant comparator to NEPA was APPA 
for HEC and PA for MEC. 
The cost-effectiveness model was developed within a 
Markov cohort structure, which is well validated and has 
been used in published CINV models [24,29]. The single-cycle 
Figure 4. Scatterplot of incremental effects and costs in HEC and MEC.
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(5-day) structure allows the model to focus on CINV-related 
consequences and to prevent the outcomes from being 
influenced by disease characteristics and other toxicities of 
chemotherapy than emetogenicity. Thus, the results from the 
analysis can be applicable to CINV management regardless of 
cancer type, cancer stage and toxicity of chemotherapy except 
emetogenicity.
Clinical trials have demonstrated that palonosetron is effective 
for the treatment of CINV as a single agent, especially following 
cisplatin-based chemotherapy [30–32]. Palonosetron is 
therefore now the gold standard for treating CINV, either as 
a single agent in MEC or in combination with an aprepitant-
based regimen in HEC [21]. Aprepitant-based regimens have 
been widely used in combination with 5-HT3 RAs, such as 
palonosetron, ondansetron or granisetron, for the treatment of 
CINV in the HEC population and are recommended by evidence-
based, European and US consensus guidelines [21–23].
This economic evaluation shows that netupitant forms a better 
combination with palonosetron compared with aprepitant, in 
terms of both cost saving and efficacy in the HEC indication. 
Netupitant plus palonosetron is also more effective in terms 
of emesis days avoided and increased health-related quality 
of life, which is an increasingly important outcome for medical 
interventions, particularly in the area of supportive care. In the 
MEC indication when NEPA is compared against palonosetron, 
the current standard of care, the ICER of £13,318 is below the 
accepted threshold for being considered cost effective in the 
UK (£20,000–30,000 per QALY gained) [33]. In the UK, the use 
of NEPA for the treatment of CINV in both MEC and HEC can 
therefore be considered a cost-effective treatment option. The 
strength of these results were supported by the consistency of 
the results across all outcomes and populations in the model and 
in the sensitivity analyses. Several studies have demonstrated 
the need for therapies that are effective in preventing both acute 
and delayed CINV [34]. CINV control in clinical practice remains 
an issue, especially in the delayed phase; delayed CINV occurred 
in 58.4% of patients receiving anti-emetic therapy and nausea 
affected 60.7% of patients treated with current anti-emetics [12]. 
Owing to the dual component of NEPA in addressing both acute 
and delayed CINV, this economic evaluation demonstrates that 
guideline-adherent prophylaxis of CINV may be regarded as a 
cost-effective investment of resources. Together with the results 
of clinical trials that demonstrate the efficacy and safety of NEPA, 
these cost-effectiveness results demonstrate the clinical utility of 
this combination therapy [35–37]. These findings may therefore 
enhance clinicians’ individual acceptance of and adherence to 
guideline recommendations, thereby leading to the optimisation 
of CINV treatment strategy within clinical practice.
The analysis had the following limitations. First, the results  
may vary based on different chemotherapy cycles, since the 
efficacy of treatments may differ. Second, the analysis was 
based on a five-day time horizon. Any cost-effectiveness, 
healthcare consumption, and quality-of-life data, which were 
acquired beyond the model’s five-day time horizon were, 
therefore, not evaluated. Third, the generic utility measure  
used may not be very sensitive to CINV-specific states and 
therefore might not have comprehensively captured the 
differences between treatment strategies. Fourth, the results 
may have to be interpreted with caution when the model  
is applied to a specific group of patients, for example, young 
and/or female cancer patients, for whom different response 
rates may be observed compared to the general cancer 
population.
Further studies are required to evaluate the use of netupitant 
in combination with palonosetron in the UK for preventing 
CINV associated with both HEC and MEC over multiple cycles. 
Ideally, the allocation of resources should be informed by a 
comprehensive assessment of all relevant direct healthcare 
costs and indirect costs. To further assess the impact of CINV 
from a societal perspective, it would be of interest to also 
incorporate indirect costs, especially costs associated with 
missed work days for patients and their caregivers, as well as 
healthcare consumption data that were captured after the five-
day time horizon used in this economic model.
In conclusion, this economic evaluation demonstrates that 
NEPA is a dominant (in HEC) and cost-effective (in MEC) 
treatment alternative to current anti-emetic standards of care 
in the UK during the first five days of chemotherapy treatment 
in cancer patients.
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Appendix 1.  Inclusion criteria.
Process Criteria
P (Patient Population) Human adults (≥18 years) cancer patients receiving highly or moderately emetogenic 
chemotherapy
I (Intervention or Exposure) Studies assessing the efficacy or safety of one of the following antiemetics:
•	 5-HT3s: palonosetron, ondansetron, granisetron, tropisetron, dolasetron, 
metoclopramide, ramosetron
•	 NK1s: aprepitant, fosaprepitant, casopitant, ezlopitant, netupitant, vestipitant
•	 Other: Olanzapine, levonantradol, lorazepam, nabilone, dronabinol, dexamethasone
C (Comparators) Placebo or active comparator
O (Outcomes) •	 At least complete response, defined as no emesis/vomiting and no rescue medication
•	 Complete protection, partial response, complete control, total control, time to first 
emetic episode, time to use of rescue medication, time to treatment failure
S (Study Design) Blinded, randomised controlled trials (≥ Phase 2) with more than 50 patients
5-HT3: 5-HT3 receptor antagonist; NK1: NK1 receptor antagonist.
Appendices
Please see next page for Appendix 2 and Appendix 3.
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Appendix 2.   Estimated response rates of the 
comparators in HEC (Reference 
efficacy was NEPA from NETU 07-07).
Complete  
response
Complete  
protection
OR 
(95% CI)
OR 
(95% CI)
Acute phase
APPAa 1.498 (0.217–6.385) 3.501 (1.088–13.263)
APR+ONDb 2.100 (0.432–11.787) 3.714(1.048–15.364)
APR+GRAc 1.917 (0.298–8.741) 4.973 (0.829–30.877)
APR+5-HT3d 1.851 (0.674–5.376) 3.501 (1.088–13.263)
OLA+PALe 0.304 (0.024–2.350) 1.000 (0.500–1.500)
PALf 3.804 (0.989–17.082) 5.228 (1.478–21.158)
ONDg 4.112 (0.761–25.003) 7.389 (1.989–31.627)
GRAh 3.494 (0.663–15.863) 5.601 (1.265–26.816)
5-HT3i 3.770 (1.361–11.023) 5.789 (1.813–21.758)
Overall phase
APPAa 2.490 (1.103–6.092) 3.501 (1.088–13.263)
APR+ONDb 1.542 (0.627–3.710) 3.714 (1.048–15.364)
APR+GRAc 3.068 (1.325–7.448) 4.973 (0.829–30.877)
APR+5-HT3d 1.817 (1.000–3.401) 3.501 (1.088–13.263)
OLA+PALe 1.970 (0.637–6.606) 1.000 (0.500–1.500)
PALf 3.394 (1.579–7.301) 5.228 (1.478–21.158)
ONDg 3.669 (1.377–9.459) 7.389 (1.989–31.627)
GRAh 5.714 (2.509–13.397) 5.601 (1.265–26.816)
5-HT3i 3.931 (2.152–7.382) 5.789 (1.813–21.758)
aaprepitant+palonosetron+dexamethasone; 
baprepitant+ondansetron+dexamethasone; 
caprepitant+granisetron+dexamethasone; 
daprepitant+5-HT3(pooled)+dexamethasone; 
eolanzapine+palonosetron+dexamethasone; 
fpalonosetron+dexamethasone; 
gondansetron+dexamethasone; 
hgranisetron+dexamethasone;  
i5-HT3+dexamethasone; CI: confidence interval; 
HEC: highly emetogenic chemotherapy; NEPA: 
netupitant+palonosetron+dexamethasone; OR: odds ratio.
Appendix 3.   Estimated response rates of the 
comparators in MEC (Reference 
efficacy was NEPA from NETU 08-18).
Complete  
response
Complete  
protection
OR 
(95% CI)
OR 
(95% CI)
Acute  
phase
APPAa 0.953 (0.337–2.692) 1.000 (0.500–1.500)
APR+5-HT3b 0.953 (0.337–2.692) 1.000 (0.500–1.500)
PALc 1.345 (0.879–2.063) 1.084 (0.745–1.577)
ONDd 1.807 (0.524–6.238) 1.084 (0.745–1.577)
GRAe 1.906 (0.135–26.939) 1.084 (0.745–1.577)
5-HT3f 1.814 (0.533–6.179) 1.084(0.745–1.577)
Overall 
phase
APPAa 0.868 (0.449–1.68) 1.000 (0.500–1.500)
APR+5-HT3b 0.868 (0.449–1.68) 1.000 (0.500–1.500)
PALc 1.450 (1.050–2.003) 1.281 (0.947–1.724)
ONDd 1.293 (0.435–3.784) 1.281 (0.947–1.724)
GRAe 1.311 (0.370–3.365) 1.281 (0.947–1.724)
5-HT3f 1.474 (0.548–2.43) 1.281 (0.947–1.724)
aaprepitant+palonosetron+dexamethasone; 
baprepitant+5-HT3(pooled)+dexamethasone; 
cpalonosetron+dexamethasone; 
dondansetron+dexamethasone; 
egranisetron+dexamethasone;  
f5-HT3+dexamethasone;  
CI: confidence interval; MEC: moderately emetogenic 
chemotherapy; NEPA: netupitant+palonosetron+ 
dexamethasone; OR: odds ratio.
